IP Library Granted Patent US 10,526,592
Granted Patent B2
US 10,526,592 · App. 15/574,559 · Granted Jan 7, 2020

Beta-galactosidase variant having high transglycosylation activity, and use thereof

Inventors: Su Jin Kim (hungcheongnam-do, KR); Young-Jae Eu (Daejeon, KR); Taek Ho Yang (Daejeon, KR); Jae Gu Pan (Sejong-si, KR); Eui Joong Kim (Daejeon, KR)
Assignee: GENOFOCUS CO., LTD.
C12N9/2402C12N15/75C12N15/80C12N15/81C12P19/04C12P19/14C12Y302/01023
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,526,592
App. No.
15/574,559
Granted
Jan 7, 2020
Kind
B2
Abstract

The present invention relates to a beta-galactosidase mutant having high transglycosylation activity and containing a C-terminal deletion, and the use thereof and more. More specifically, the present invention relates to a beta-galactosidase mutant having a C-terminal deletion, a gene encoding the same, a recombinant vector containing the gene, a recombinant microorganism transformed with the gene or the recombinant vector, and a method for producing the beta-galactosidase mutant using the recombinant microorganism. Using the high transglycosylation activity of the beta-galactosidase mutant containing the C-terminal deletion according to the present invention, galactooligosaccharide can be efficiently produced in large amounts.

Claims (21)

1. A beta-galactosidase mutant having improved thermal stability or enzymatic activity compared to a wild-type beta-galactosidase set forth in the amino acid sequence of SEQ ID NO: 3 by deleting C-terminus of a beta-galactosidase set forth in the amino acid sequence of SEQ ID NO: 3, wherein the deletion of C-terminus is one or more selected from the group consisting of:

a) a C-terminal deletion mutation after amino acid residue 799;

b) a C-terminal deletion mutation after amino acid residue 873;

c) a C-terminal deletion mutation after amino acid residue 950;

d) a C-terminal deletion mutation alter amino acid residue 1000;

e) a C-terminal deletion mutation after amino acid residue 1059;

f) a C-terminal deletion mutation after amino acid residue 1066;

g) a C-terminal deletion mutation after amino acid residue 1115;

h) a C-terminal deletion mutation after amino acid residue 1164;

i) a C-terminal deletion mutation after amino acid residue 1302; and

j) a C-terminal deletion mutation after amino acid residue 1350.

2. The beta-galactosidase mutant of claim 1 , wherein the amino acid sequence of the mutant is SEQ ID NOs: 4, 6, 10, 12, 14, 16, 18, 20, 24 or 26.

3. A gene encoding a beta-galactosidase mutant of claim 1 .

4. A recombinant microorganism into which the gene of claim 3 or a recombinant vector comprising the gene of claim 3 is introduced.

5. The recombinant microorganism of claim 4 , wherein said microorganism is Bacillus subtillis.

6. A method for producing a beta-galactosidase mutant, comprising the steps of:

expressing the beta-galactosidase mutant by culturing the recombinant microorganism of claim 4 ; and

recovering the expressed beta-galactosidase mutant.

7. A method for producing a galactooligosaccharide, comprising:

reacting a lactose-containing substrate with a beta-galactosidase mutant of claim 1 to produce galactooligosaccharide; and

recovering the produced galactooligosaccharide.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2017
From: KIM, SU JIN; EU, YOUNG-JAE; YANG, TAEK HO; PAN, JAE GU; KIM, EUI JOONG
To: GENOFOCUS CO., LTD.
Reel/Frame 044325/0074 →
Priority Claims (1)
KR 10-2015-0074862 · May 28, 2015 · national
Continuity (1)
Related Publication 20180155699A1 · Jun 7, 2018